SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001654954-20-008642
Filing Date
2020-08-07
Accepted
2020-08-07 16:43:32
Documents
5
Period of Report
2020-09-11
Effectiveness Date
2020-08-07

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT azrxdef14a_sep112020.htm DEF 14A 828191
2 IMAGE azrxdef14a_sep112020000.jpg GRAPHIC 5420
3 IMAGE azrxdef14a_sep112020001.jpg GRAPHIC 7453
4 IMAGE proxycard000.jpg GRAPHIC 75072
5 IMAGE proxycard001.jpg GRAPHIC 69357
  Complete submission text file 0001654954-20-008642.txt   1046543
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37853 | Film No.: 201085444
SIC: 2834 Pharmaceutical Preparations